United States In-Vitro Diagnostics Market Report by Test Types, Products, Application and Company Analysis 2026-2034
Description
USA In-Vitro Diagnostics Market Size and Forecast 2026–2034
The United States in vitro diagnostics market is expected to grow during the forecast period due to the rising incidence of chronic and infectious diseases and the need for early and accurate diagnosis of diseases. Moreover, ongoing technological developments in in vitro diagnostics are also expected to drive the demand for the services in the United States. Therefore, the market is expected to grow from US$42.37 Billion in 2025 to US$ 65.96 Billion in 2034 at a compound annual growth rate of 5.04% during the period from 2026-2034 due to the ongoing demand for in vitro diagnostics.
United States IVD Market Overview
IVD involves the diagnostic practice of conducting tests on biological samples such as blood, urine, saliva, and even tissue extracted from the human body. IVD tests are very crucial in diagnosing diseases, monitoring health, treatment, and wellness in an individual. Instruments, reagents, test kits, and software are included in IVD products used in various applications such as clinical chemistry, immunoassays, molecular diagnostics, hematology, and microbiology. IVD stands out as an important tool in early diagnostics, personalized medicine, and preventive medicine.
The in vitro diagnostics market is very popular in the United States due to the high acoustic healthcare infrastructure and the emphasis on early and accurate diagnosis. The prevalence of chronic diseases, like diabetes, cardiovascular diseases, and cancer, is very high in the United States, and because of that, it presents a consistent demand for diagnostic tests. The United States is also leading in molecular diagnostics, genetic testing, and point-of-care testing. R&D, favorable reimbursement policies, and the adoption of preventive health screenings also contribute to the growth of the in vitro diagnostics market.
Growth Drivers of the United States In Vitro Diagnostics Market
High Burden of Chronic and Infectious Diseases
The main cause of death due to chronic and non-communicable diseases can be seen at the global level. These are the main causes of death in the United States as well, accounting for 8 out of the top 10 causes of death. The rising incidence of chronic and non-communicable diseases is one of the significant factors that contribute to the growth of the IVD market in the United States. Diseases that come under the chronic and non-communicable category, which require frequent testing, are diabetes, cardiovascular, cancer, and autoimmune disorders. These are regularly tested to monitor and diagnose them at early stages. Outbreaks of infectious diseases, though common, become problematic at specific intervals, thereby requiring testing, a requirement that contributes to the demand for IVD products in the United States. The increasing population of the geriatric cohort also contributes significantly to the demand, as geriatric patients are required to regularly undergo tests to monitor and diagnose various disorders. Of the US population, an estimated 129 million have at least 1 major chronic disease, as defined by the US Department of Health and Human Services, which includes heart disease, cancer, diabetes, obesity, and hypertension. An increasing proportion of the population in America is living with multiple chronic diseases: 42% of that population has 2 or more, and 12% have at least 5. In addition to the toll it takes on individuals, chronic disease has a significant impact on the US healthcare system. Some 90% of the $4.1 trillion spent on healthcare in a year is devoted to the management of chronic diseases and mental health.
Advanced Healthcare Infrastructure and Technological Leadership
The US has one of the most developed healthcare infrastructures in the world, which is a major positive factor in the growth of the IVD market. Hospitals, esoteric labs, and diagnostic facilities quickly adopt novel technologies, including molecular diagnostics, next-generation sequencing, and automated immunoassays. The US is a world leader in R&D, fueling innovation in terms of diagnostic precision, speed, and personalization. The intersection of digital health with artificial intelligence and laboratory automation boosts efficiency and productivity. World-class IVD companies and research institutions around the country drive fast innovation and adoption. Oct 2025, Eleos, the AI leader in post-acute care, today announced the launch of Polaris AI, developed in collaboration with Google Cloud technology. Polaris AI leverages Google Cloud's family of multimodal models and is built on its secure, scalable infrastructure, combined with Eleos' purpose-built dataset of millions of real-world behavioral health sessions. Eleos is bringing to market one of the most advanced foundational AI models developed specifically for the post-acute care space, from growing clinician burnout to increasing regulatory pressures across the behavioral health, substance use disorder (SUD), home health, and hospice care sectors.
Emphasis on Preventive Care and Personalized Medicine
The rising trend in preventive healthcare services, which has become increasingly popular among individuals due to its benefits, is one of the factors that is driving the IVD market in the United States. A preventive healthcare approach – preventive testing, early disease detection, and risk assessment – provides essential benefits in value-based healthcare. Diagnostic tests enable healthcare practitioners to detect disease states early, thus making healthcare less expensive in the long run. Individualized medicine, a new era in medical treatment, has also contributed significantly towards the expansion of the IVD market. The interest in targeted therapies with molecular and genetic tests will continue to increase in response to the rising trend in individualized medicine. Individualized medicine requires an innovative approach, and with the rising trend in individualized healthcare, healthcare solutions will continue to adopt advanced technologies. On September 9, 2025, Tempus AI, Inc., a technology company at the forefront of applying AI to improve healthcare through the accelerated adoption of AI, announced that it received 510(k) clearance from the U.S. FDA to market the company's RNA-based Tempus xR IVD product. It will be marketed as a Life Sciences Tool to assist drug development programs.
Challenges of the United States in vitro diagnostics (IVD) market
Stringent Regulatory Framework and Lengthy Approval Processes
One of the major challenges in the United States IVD market is the strict regulatory framework surrounding the development of diagnostic products. Indeed, the IVD industry has to follow a number of strict regulatory requirements as stipulated by relevant authorities. For example, this involves rigorous clinical validation, quality control, and also post-market surveillance. The approval of diagnostic products takes time and is expensive. This slows down the time for launching new diagnostic products in the market. Small companies and startups can find it difficult adhering to the strict regulatory requirements set by relevant authorities. This is because they lack the capacity to meet the requirements. There is also regulatory ambiguity with regard to laboratory-developed tests.
Pricing Pressure and Reimbursement Limitations
One of the major challenges for the US IVD industry is pricing forces and reimbursement limitations. With the increasing drive for cost containment and value-based care across the healthcare industry, highly advanced diagnostic procedures may have their reimbursement limited. Molecular and genetic diagnostics, which tend to be very expensive, will likely have limited or lower reimbursement rates, thus discouraging them from being adopted. The diagnostic laboratories face a challenge in balancing the development of innovative tests with financial sustainability. These pricing forces ultimately have an impact on profit margins for the manufacturers. Reimbursement policies and value proposition remain one of the major challenges within the US IVD industry.
USA ELISA & CLIA IVD Market
The ELISA and CLIA IVD market in the United States is a developed market with high demand due to the need for precision, sensitivity, and automation carried out during the tests. Immunoassays are commonly used as a approach for diagnosing infections, hormone assays, oncology, and autoimmune disorders. This segment is becoming more popular as CLIA systems are more sensitive, have a short turnaround time, and are automatable. This technique is fully embraced and incorporated in many hospital labs and reference labs, offering efficiency and allowing them to handle multiple tests. The rapid advancements made in technology, enabling multiplexing and increasing the ability of the assays, have increased the demand in the ELISA and CLIA IVD market, especially in the United States. The prominent players of the IVD market and the adoption of advanced diagnostics make it a significant contribution to the ELISA and CLIA IVD market.
USA In Vitro Diagnostics Rapid Test Market
The US rapid test IVD market is growing steadily, driven by increased demand for convenient diagnostic tests. Rapid tests are primarily used for centralized facilities such as emergency room situations, clinics, pharmacies, and home use for conditions such as infectious disease, pregnancy, glucose, and cardiac markers. The trend towards decentralized medicine and timely diagnosis also drives demand for rapid tests. The COVID-19 outbreak has fueled demand for rapid diagnostic tests, accelerating their usage and demand. Advances in lateral flow and digital connectivity are also helping to provide more accurate rapid tests. The trend towards consumers and healthcare professionals seeking faster answers will continue to support growth for rapid tests, another important area for the US IVD market.
USA In Vitro Diagnostics Reagents Market
The IVD reagents market in the United States is an important and regular source of revenue. Reagents are essential and play an indispensable role in all kinds of diagnostic tests, whether they be immunoassays, clinical chemistry, molecular diagnostics, or hematology. Large volumes of testing, due to the need for monitoring and surveillance of chronic diseases, as well as preventive and health checks, ensure a steady demand for reagents. It is prudent for laboratories to have on hand reliable and quality reagents to guarantee the accuracy of test results with uniformity in their standards. Advances in technology in automated analyzers also contribute to increased reagent demand.
USA IVD Clinical Chemistry Market
The clinical chemistry market for IVD in the US is one of the largest diagnostic markets in the country. Clinical chemistry tests like blood glucose levels, blood cholesterol levels, liver function tests, and electrolyte tests form the foundation of the diagnosis and treatment of chronic diseases. The high incidence of diabetes, obesity, and cardiovascular diseases is also fueling the market for clinical chemistry tests in the US. There is also an increasing trend of hospitals using automated analyzers to perform clinical chemistry tests. In addition to this, preventive healthcare is also driving the market for clinical chemistry tests to some extent too. Clinical chemistry is a basic service of the US healthcare infrastructure.
USA Microbiology IVD Market
The microbiology IVD market in the US is driven by the need to accurately identify infectious pathogens and monitor antimicrobial resistance. The need to perform microbiology tests is a critical need within a hospital, a reference laboratory, and a public health setting. The knowledge of hospital-acquired infections and emerging infectious disease is on the rise, which fuels the need for these tests. The necessity to automate culture systems, molecular microbiology, and rapid pathogen identification systems improves the accuracy of the tests. The need to perform these tests can be fueled by the importance of managing infectious diseases; hence, the microbiology IVD market is growing.
California IVD Market
The California market is one of the largest US markets for IVD products. The reasons for this are its well-developed infrastructure, advanced R&D facilities, and a strong base of biotech companies. There is a strong presence of academic medical centers, reference labs, and diagnostic startup companies that aggressively seek to incorporate latest technology in IVD testing. The prevalence of chronic diseases, cancer research institutes, and preventive public health programs contribute to testing demand. It is also a leader in molecular diagnostics, genetic testing, and precision medicine due to innovation centers like Silicon Valley and San Diego. With constant innovation happening in medicine and life sciences, California is significant to overall US market growth.
Texas IVD Market
The Texas IVD market is also driven by the presence of the large and varied population base of Texas, along with the evolving healthcare infrastructure. The growing prevalence of chronic conditions such as diabetes and cardiovascular disorders drives the need for routine and advanced diagnostic tests. Texas is also home to numerous hospitals, diagnostic labs, and medical facilities, thereby allowing for high volumes of diagnostic tests. The establishment of private healthcare facilities and reference labs also plays a part in growing the Texas IVD market. The need for improving access to healthcare facilities, irrespective of rural locations, also aids the usage of point of care rapid diagnostic tests in Texas. Texas ranks amongst some of the top-growing IVD markets.
Florida IVD Market
The large population of elderly citizens propels the Florida IVD market, driving demand for chronic disease care and preventive healthcare. Diagnostic tests for cardiovascular diseases, diabetes, cancer, and infectious diseases are in great demand. A well-established infrastructure of providers within Florida means a good volume of tests is guaranteed due to an extensive network of healthcare providers, diagnostic facilities, and specialty care centers. The seasonal population variations due to tourists and retirees boost healthcare usage. Point-of-care testing and home diagnostics are becoming increasingly popular. With the growth in the importance of preventive healthcare and early disease diagnosis, the demand in the Florida IVD market is increasing steadily.
Washington IVD Market
The market for IVD products in Washington is driven by a strong focus on research, technology, and innovation. The state is home to various top research centers, tech companies, and healthcare institutions. These institutions show strong interest in the adoption of advanced technology in IVD products. Such demand comes from research on infectious diseases, cancer, and personalized medicine. The state’s strong focus on public health programs and disease surveillance also boosts the demand for microbiology and molecular diagnostics. Innovation, technology, and research between research centers and for-profit organizations aid each other to boost the adoption of advanced IVD product technology. Keeping up with the rapid advancement of technology, the state of Washington continues to play a major role in the IVD product market.
Market Segmentation
Test Types
• ELISA & CLIA
• PCR
• Rapid Test
• Fluorescence Immunoassays (FIA)
• In Situ Hybridization
• Transcription Mediated Amplification
• Sequencing
• Colorimetric Immunoassay
• Radioimmunoassay (RIA)
• Isothermal Nucleic Acid Amplification Technology
• Others
Product
• Reagents
• Instruments
• Services
Application
• Immunochemistry
• Clinical Chemistry
• Hematology
• Coagulation
• Molecular Diagnostics
• Microbiology
• Others
Top States
• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States
All companies have been covered with 5 Viewpoints
• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis
Company Analysis:
• Roche Diagnostics
• Danaher Corporation
• Thermofisher Scientific Inc.
• Bio–Rad Laboratories, Inc.
• Biomerieux
• Abbott Laboratories
• Sysmex Corporation
The United States in vitro diagnostics market is expected to grow during the forecast period due to the rising incidence of chronic and infectious diseases and the need for early and accurate diagnosis of diseases. Moreover, ongoing technological developments in in vitro diagnostics are also expected to drive the demand for the services in the United States. Therefore, the market is expected to grow from US$42.37 Billion in 2025 to US$ 65.96 Billion in 2034 at a compound annual growth rate of 5.04% during the period from 2026-2034 due to the ongoing demand for in vitro diagnostics.
United States IVD Market Overview
IVD involves the diagnostic practice of conducting tests on biological samples such as blood, urine, saliva, and even tissue extracted from the human body. IVD tests are very crucial in diagnosing diseases, monitoring health, treatment, and wellness in an individual. Instruments, reagents, test kits, and software are included in IVD products used in various applications such as clinical chemistry, immunoassays, molecular diagnostics, hematology, and microbiology. IVD stands out as an important tool in early diagnostics, personalized medicine, and preventive medicine.
The in vitro diagnostics market is very popular in the United States due to the high acoustic healthcare infrastructure and the emphasis on early and accurate diagnosis. The prevalence of chronic diseases, like diabetes, cardiovascular diseases, and cancer, is very high in the United States, and because of that, it presents a consistent demand for diagnostic tests. The United States is also leading in molecular diagnostics, genetic testing, and point-of-care testing. R&D, favorable reimbursement policies, and the adoption of preventive health screenings also contribute to the growth of the in vitro diagnostics market.
Growth Drivers of the United States In Vitro Diagnostics Market
High Burden of Chronic and Infectious Diseases
The main cause of death due to chronic and non-communicable diseases can be seen at the global level. These are the main causes of death in the United States as well, accounting for 8 out of the top 10 causes of death. The rising incidence of chronic and non-communicable diseases is one of the significant factors that contribute to the growth of the IVD market in the United States. Diseases that come under the chronic and non-communicable category, which require frequent testing, are diabetes, cardiovascular, cancer, and autoimmune disorders. These are regularly tested to monitor and diagnose them at early stages. Outbreaks of infectious diseases, though common, become problematic at specific intervals, thereby requiring testing, a requirement that contributes to the demand for IVD products in the United States. The increasing population of the geriatric cohort also contributes significantly to the demand, as geriatric patients are required to regularly undergo tests to monitor and diagnose various disorders. Of the US population, an estimated 129 million have at least 1 major chronic disease, as defined by the US Department of Health and Human Services, which includes heart disease, cancer, diabetes, obesity, and hypertension. An increasing proportion of the population in America is living with multiple chronic diseases: 42% of that population has 2 or more, and 12% have at least 5. In addition to the toll it takes on individuals, chronic disease has a significant impact on the US healthcare system. Some 90% of the $4.1 trillion spent on healthcare in a year is devoted to the management of chronic diseases and mental health.
Advanced Healthcare Infrastructure and Technological Leadership
The US has one of the most developed healthcare infrastructures in the world, which is a major positive factor in the growth of the IVD market. Hospitals, esoteric labs, and diagnostic facilities quickly adopt novel technologies, including molecular diagnostics, next-generation sequencing, and automated immunoassays. The US is a world leader in R&D, fueling innovation in terms of diagnostic precision, speed, and personalization. The intersection of digital health with artificial intelligence and laboratory automation boosts efficiency and productivity. World-class IVD companies and research institutions around the country drive fast innovation and adoption. Oct 2025, Eleos, the AI leader in post-acute care, today announced the launch of Polaris AI, developed in collaboration with Google Cloud technology. Polaris AI leverages Google Cloud's family of multimodal models and is built on its secure, scalable infrastructure, combined with Eleos' purpose-built dataset of millions of real-world behavioral health sessions. Eleos is bringing to market one of the most advanced foundational AI models developed specifically for the post-acute care space, from growing clinician burnout to increasing regulatory pressures across the behavioral health, substance use disorder (SUD), home health, and hospice care sectors.
Emphasis on Preventive Care and Personalized Medicine
The rising trend in preventive healthcare services, which has become increasingly popular among individuals due to its benefits, is one of the factors that is driving the IVD market in the United States. A preventive healthcare approach – preventive testing, early disease detection, and risk assessment – provides essential benefits in value-based healthcare. Diagnostic tests enable healthcare practitioners to detect disease states early, thus making healthcare less expensive in the long run. Individualized medicine, a new era in medical treatment, has also contributed significantly towards the expansion of the IVD market. The interest in targeted therapies with molecular and genetic tests will continue to increase in response to the rising trend in individualized medicine. Individualized medicine requires an innovative approach, and with the rising trend in individualized healthcare, healthcare solutions will continue to adopt advanced technologies. On September 9, 2025, Tempus AI, Inc., a technology company at the forefront of applying AI to improve healthcare through the accelerated adoption of AI, announced that it received 510(k) clearance from the U.S. FDA to market the company's RNA-based Tempus xR IVD product. It will be marketed as a Life Sciences Tool to assist drug development programs.
Challenges of the United States in vitro diagnostics (IVD) market
Stringent Regulatory Framework and Lengthy Approval Processes
One of the major challenges in the United States IVD market is the strict regulatory framework surrounding the development of diagnostic products. Indeed, the IVD industry has to follow a number of strict regulatory requirements as stipulated by relevant authorities. For example, this involves rigorous clinical validation, quality control, and also post-market surveillance. The approval of diagnostic products takes time and is expensive. This slows down the time for launching new diagnostic products in the market. Small companies and startups can find it difficult adhering to the strict regulatory requirements set by relevant authorities. This is because they lack the capacity to meet the requirements. There is also regulatory ambiguity with regard to laboratory-developed tests.
Pricing Pressure and Reimbursement Limitations
One of the major challenges for the US IVD industry is pricing forces and reimbursement limitations. With the increasing drive for cost containment and value-based care across the healthcare industry, highly advanced diagnostic procedures may have their reimbursement limited. Molecular and genetic diagnostics, which tend to be very expensive, will likely have limited or lower reimbursement rates, thus discouraging them from being adopted. The diagnostic laboratories face a challenge in balancing the development of innovative tests with financial sustainability. These pricing forces ultimately have an impact on profit margins for the manufacturers. Reimbursement policies and value proposition remain one of the major challenges within the US IVD industry.
USA ELISA & CLIA IVD Market
The ELISA and CLIA IVD market in the United States is a developed market with high demand due to the need for precision, sensitivity, and automation carried out during the tests. Immunoassays are commonly used as a approach for diagnosing infections, hormone assays, oncology, and autoimmune disorders. This segment is becoming more popular as CLIA systems are more sensitive, have a short turnaround time, and are automatable. This technique is fully embraced and incorporated in many hospital labs and reference labs, offering efficiency and allowing them to handle multiple tests. The rapid advancements made in technology, enabling multiplexing and increasing the ability of the assays, have increased the demand in the ELISA and CLIA IVD market, especially in the United States. The prominent players of the IVD market and the adoption of advanced diagnostics make it a significant contribution to the ELISA and CLIA IVD market.
USA In Vitro Diagnostics Rapid Test Market
The US rapid test IVD market is growing steadily, driven by increased demand for convenient diagnostic tests. Rapid tests are primarily used for centralized facilities such as emergency room situations, clinics, pharmacies, and home use for conditions such as infectious disease, pregnancy, glucose, and cardiac markers. The trend towards decentralized medicine and timely diagnosis also drives demand for rapid tests. The COVID-19 outbreak has fueled demand for rapid diagnostic tests, accelerating their usage and demand. Advances in lateral flow and digital connectivity are also helping to provide more accurate rapid tests. The trend towards consumers and healthcare professionals seeking faster answers will continue to support growth for rapid tests, another important area for the US IVD market.
USA In Vitro Diagnostics Reagents Market
The IVD reagents market in the United States is an important and regular source of revenue. Reagents are essential and play an indispensable role in all kinds of diagnostic tests, whether they be immunoassays, clinical chemistry, molecular diagnostics, or hematology. Large volumes of testing, due to the need for monitoring and surveillance of chronic diseases, as well as preventive and health checks, ensure a steady demand for reagents. It is prudent for laboratories to have on hand reliable and quality reagents to guarantee the accuracy of test results with uniformity in their standards. Advances in technology in automated analyzers also contribute to increased reagent demand.
USA IVD Clinical Chemistry Market
The clinical chemistry market for IVD in the US is one of the largest diagnostic markets in the country. Clinical chemistry tests like blood glucose levels, blood cholesterol levels, liver function tests, and electrolyte tests form the foundation of the diagnosis and treatment of chronic diseases. The high incidence of diabetes, obesity, and cardiovascular diseases is also fueling the market for clinical chemistry tests in the US. There is also an increasing trend of hospitals using automated analyzers to perform clinical chemistry tests. In addition to this, preventive healthcare is also driving the market for clinical chemistry tests to some extent too. Clinical chemistry is a basic service of the US healthcare infrastructure.
USA Microbiology IVD Market
The microbiology IVD market in the US is driven by the need to accurately identify infectious pathogens and monitor antimicrobial resistance. The need to perform microbiology tests is a critical need within a hospital, a reference laboratory, and a public health setting. The knowledge of hospital-acquired infections and emerging infectious disease is on the rise, which fuels the need for these tests. The necessity to automate culture systems, molecular microbiology, and rapid pathogen identification systems improves the accuracy of the tests. The need to perform these tests can be fueled by the importance of managing infectious diseases; hence, the microbiology IVD market is growing.
California IVD Market
The California market is one of the largest US markets for IVD products. The reasons for this are its well-developed infrastructure, advanced R&D facilities, and a strong base of biotech companies. There is a strong presence of academic medical centers, reference labs, and diagnostic startup companies that aggressively seek to incorporate latest technology in IVD testing. The prevalence of chronic diseases, cancer research institutes, and preventive public health programs contribute to testing demand. It is also a leader in molecular diagnostics, genetic testing, and precision medicine due to innovation centers like Silicon Valley and San Diego. With constant innovation happening in medicine and life sciences, California is significant to overall US market growth.
Texas IVD Market
The Texas IVD market is also driven by the presence of the large and varied population base of Texas, along with the evolving healthcare infrastructure. The growing prevalence of chronic conditions such as diabetes and cardiovascular disorders drives the need for routine and advanced diagnostic tests. Texas is also home to numerous hospitals, diagnostic labs, and medical facilities, thereby allowing for high volumes of diagnostic tests. The establishment of private healthcare facilities and reference labs also plays a part in growing the Texas IVD market. The need for improving access to healthcare facilities, irrespective of rural locations, also aids the usage of point of care rapid diagnostic tests in Texas. Texas ranks amongst some of the top-growing IVD markets.
Florida IVD Market
The large population of elderly citizens propels the Florida IVD market, driving demand for chronic disease care and preventive healthcare. Diagnostic tests for cardiovascular diseases, diabetes, cancer, and infectious diseases are in great demand. A well-established infrastructure of providers within Florida means a good volume of tests is guaranteed due to an extensive network of healthcare providers, diagnostic facilities, and specialty care centers. The seasonal population variations due to tourists and retirees boost healthcare usage. Point-of-care testing and home diagnostics are becoming increasingly popular. With the growth in the importance of preventive healthcare and early disease diagnosis, the demand in the Florida IVD market is increasing steadily.
Washington IVD Market
The market for IVD products in Washington is driven by a strong focus on research, technology, and innovation. The state is home to various top research centers, tech companies, and healthcare institutions. These institutions show strong interest in the adoption of advanced technology in IVD products. Such demand comes from research on infectious diseases, cancer, and personalized medicine. The state’s strong focus on public health programs and disease surveillance also boosts the demand for microbiology and molecular diagnostics. Innovation, technology, and research between research centers and for-profit organizations aid each other to boost the adoption of advanced IVD product technology. Keeping up with the rapid advancement of technology, the state of Washington continues to play a major role in the IVD product market.
Market Segmentation
Test Types
• ELISA & CLIA
• PCR
• Rapid Test
• Fluorescence Immunoassays (FIA)
• In Situ Hybridization
• Transcription Mediated Amplification
• Sequencing
• Colorimetric Immunoassay
• Radioimmunoassay (RIA)
• Isothermal Nucleic Acid Amplification Technology
• Others
Product
• Reagents
• Instruments
• Services
Application
• Immunochemistry
• Clinical Chemistry
• Hematology
• Coagulation
• Molecular Diagnostics
• Microbiology
• Others
Top States
• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States
All companies have been covered with 5 Viewpoints
• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis
Company Analysis:
• Roche Diagnostics
• Danaher Corporation
• Thermofisher Scientific Inc.
• Bio–Rad Laboratories, Inc.
• Biomerieux
• Abbott Laboratories
• Sysmex Corporation
Table of Contents
200 Pages
- 1. Introduction
- 2. Research & Methodology
- 2.1 Data Source
- 2.1.1 Primary Sources
- 2.1.2 Secondary Sources
- 2.2 Research Approach
- 2.2.1 Top-Down Approach
- 2.2.2 Bottom-Up Approach
- 2.3 Forecast Projection Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
- 5. United States In Vitro Diagnostics Market
- 5.1 Historical Market
- 5.2 Market Forecast
- 6. Market Share Analysis
- 6.1 By Test Types
- 6.2 By Products
- 6.3 By Application
- 6.4 By States
- 7. Test Types
- 7.1 ELISA & CLIA
- 7.1.1 Historical Market
- 7.1.2 Market Forecast
- 7.2 PCR
- 7.2.1 Historical Market
- 7.2.2 Market Forecast
- 7.3 Rapid Test
- 7.3.1 Historical Market
- 7.3.2 Market Forecast
- 7.4 Fluorescence Immunoassays (FIA)
- 7.4.1 Historical Market
- 7.4.2 Market Forecast
- 7.5 In Situ Hybridization
- 7.5.1 Historical Market
- 7.5.2 Market Forecast
- 7.6 Transcription Mediated Amplification
- 7.6.1 Historical Market
- 7.6.2 Market Forecast
- 7.7 Sequencing
- 7.7.1 Historical Market
- 7.7.2 Market Forecast
- 7.8 Colorimetric Immunoassay
- 7.8.1 Historical Market
- 7.8.2 Market Forecast
- 7.9 Radioimmunoassay (RIA)
- 7.9.1 Historical Market
- 7.9.2 Market Forecast
- 7.10 Isothermal Nucleic Acid Amplification Technology
- 7.10.1 Historical Market
- 7.10.2 Market Forecast
- 7.11 Others
- 7.11.1 Historical Market
- 7.11.2 Market Forecast
- 8. Products
- 8.1 Reagents
- 8.1.1 Historical Market
- 8.1.2 Market Forecast
- 8.2 Instruments
- 8.2.1 Historical Market
- 8.2.2 Market Forecast
- 8.3 Services
- 8.3.1 Historical Market
- 8.3.2 Market Forecast
- 9. Application
- 9.1 Immunochemistry
- 9.1.1 Historical Market
- 9.1.2 Market Forecast
- 9.2 Clinical Chemistry
- 9.2.1 Historical Market
- 9.2.2 Market Forecast
- 9.3 Hematology
- 9.3.1 Historical Market
- 9.3.2 Market Forecast
- 9.4 Coagulation
- 9.4.1 Historical Market
- 9.4.2 Market Forecast
- 9.5 Molecular Diagnostics
- 9.5.1 Historical Market
- 9.5.2 Market Forecast
- 9.6 Microbiology
- 9.6.1 Historical Market
- 9.6.2 Market Forecast
- 9.7 Others
- 9.7.1 Historical Market
- 9.7.2 Market Forecast
- 10. States
- 10.1 California
- 10.1.1 Historical Market
- 10.1.2 Market Forecast
- 10.2 Texas
- 10.2.1 Historical Market
- 10.2.2 Market Forecast
- 10.3 New York
- 10.3.1 Historical Market
- 10.3.2 Market Forecast
- 10.4 Florida
- 10.4.1 Historical Market
- 10.4.2 Market Forecast
- 10.5 Illinois
- 10.5.1 Historical Market
- 10.5.2 Market Forecast
- 10.6 Pennsylvania
- 10.6.1 Historical Market
- 10.6.2 Market Forecast
- 10.7 Ohio
- 10.7.1 Historical Market
- 10.7.2 Market Forecast
- 10.8 Georgia
- 10.8.1 Historical Market
- 10.8.2 Market Forecast
- 10.9 New Jersey
- 10.9.1 Historical Market
- 10.9.2 Market Forecast
- 10.10 Washington
- 10.10.1 Historical Market
- 10.10.2 Market Forecast
- 10.11 North Carolina
- 10.11.1 Historical Market
- 10.11.2 Market Forecast
- 10.12 Massachusetts
- 10.12.1 Historical Market
- 10.12.2 Market Forecast
- 10.13 Virginia
- 10.13.1 Historical Market
- 10.13.2 Market Forecast
- 10.14 Michigan
- 10.14.1 Historical Market
- 10.14.2 Market Forecast
- 10.15 Maryland
- 10.15.1 Historical Market
- 10.15.2 Market Forecast
- 10.16 Colorado
- 10.16.1 Historical Market
- 10.16.2 Market Forecast
- 10.17 Tennessee
- 10.17.1 Historical Market
- 10.17.2 Market Forecast
- 10.18 Indiana
- 10.18.1 Historical Market
- 10.18.2 Market Forecast
- 10.19 Arizona
- 10.19.1 Historical Market
- 10.19.2 Market Forecast
- 10.20 Minnesota
- 10.20.1 Historical Market
- 10.20.2 Market Forecast
- 10.21 Wisconsin
- 10.21.1 Historical Market
- 10.21.2 Market Forecast
- 10.22 Missouri
- 10.22.1 Historical Market
- 10.22.2 Market Forecast
- 10.23 Connecticut
- 10.23.1 Historical Market
- 10.23.2 Market Forecast
- 10.24 South Carolina
- 10.24.1 Historical Market
- 10.24.2 Market Forecast
- 10.25 Oregon
- 10.25.1 Historical Market
- 10.25.2 Market Forecast
- 10.26 Louisiana
- 10.26.1 Historical Market
- 10.26.2 Market Forecast
- 10.27 Alabama
- 10.27.1 Historical Market
- 10.27.2 Market Forecast
- 10.28 Kentucky
- 10.28.1 Historical Market
- 10.28.2 Market Forecast
- 10.29 Rest of United States
- 10.29.1 Historical Market
- 10.29.2 Market Forecast
- 11. Porter’s Five Analysis
- 11.1 Bargaining Power of Buyers
- 11.2 Bargaining Power of Suppliers
- 11.3 Degree of Rivalry
- 11.4 Threat of New Entrants
- 11.5 Threat of Substitutes
- 12. SWOT Analysis
- 12.1 Strength
- 12.2 Weakness
- 12.3 Opportunity
- 12.4 Threat
- 13. Company Analysis
- 13.1 Roche Diagnostics
- 13.1.1 Overview
- 13.1.2 Key Persons
- 13.1.3 Recent Development
- 13.1.4 SWOT Analysis
- 13.1.5 Revenue
- 13.2 Danaher Corporation
- 13.2.1 Overview
- 13.2.2 Key Persons
- 13.2.3 Recent Development
- 13.2.4 SWOT Analysis
- 13.2.5 Revenue
- 13.3 Thermofisher Scientific Inc.
- 13.3.1 Overview
- 13.3.2 Key Persons
- 13.3.3 Recent Development
- 13.3.4 SWOT Analysis
- 13.3.5 Revenue
- 13.4 Bio–Rad Laboratories, Inc
- 13.4.1 Overview
- 13.4.2 Key Persons
- 13.4.3 Recent Development
- 13.4.4 SWOT Analysis
- 13.4.5 Revenue
- 13.5 Biomerieux
- 13.5.1 Overview
- 13.5.2 Key Persons
- 13.5.3 Recent Development
- 13.5.4 SWOT Analysis
- 13.5.5 Revenue
- 13.6 Abbott Laboratories
- 13.6.1 Overview
- 13.6.2 Key Persons
- 13.6.3 Recent Development
- 13.6.4 SWOT Analysis
- 13.6.5 Revenue
- 13.7 Sysmex Corporation
- 13.7.1 Overview
- 13.7.2 Key Persons
- 13.7.3 Recent Development
- 13.7.4 SWOT Analysis
- 13.7.5 Revenue
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
